Methods for prevention and treatment of conditions arising from local estrogen deficiency
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
An estrogen deficiency, estrogen technology, applied in sexual diseases, pharmaceutical formulations, urinary system diseases, etc., can solve problems such as little information, dyspareunia during menopause, etc.
Inactive Publication Date: 2009-04-22
WYETH LLC
View PDF3 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, beyond the studies mentioned above, there is little information on the effects of newer, low-dose hormone therapy on menopausal dyspareunia, sexual function, and other QoL-related parameters
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0142] daily application (0.3 mg conjugated estrogen / 1.5 mg medroxyprogesterone acetate) and vaginal creams to treat dyspareunia
[0143] Administer once daily on a continuous basis to perimenopausal and postmenopausal women diagnosed with vaginal dryness and / or dyspareunia (0.3 mg conjugated estrogen / 1.5 mg medroxyprogesterone acetate) until these or other menopausal symptoms no longer require treatment. Women are also administered on a daily or intermittent basis during treatment (conjugated estrogen) vaginal cream.
Embodiment 2
[0145] daily application (0.45 mg conjugated estrogen / 1.5 mg medroxyprogesterone acetate) and vaginal creams to treat dyspareunia
[0146] Administer once daily on a continuous basis to perimenopausal and postmenopausal women diagnosed with vaginal dryness and / or dyspareunia (0.45 mg conjugated estrogen / 1.5 mg medroxyprogesterone acetate) until these or other menopausal symptoms no longer require treatment. During treatment, women are also administered on a daily or intermittent basis (conjugated estrogen) vaginal cream.
Embodiment 3
[0148] daily application (0.625 mg conjugated estrogen / 2.5 mg medroxyprogesterone acetate) and vaginal creams to treat dyspareunia
[0149] Administer once daily on a continuous basis to perimenopausal and postmenopausal women diagnosed with vaginal dryness and / or dyspareunia (0.625 mg conjugated estrogen / 2.5 mg medroxyprogesterone acetate) until these or other menopausal symptoms no longer require treatment. During treatment, women are also administered on a daily or intermittent basis (conjugated estrogen) vaginal cream.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The present invention relates to methods for the prevention and treatment of conditions arising from local estrogen deficiency, such as dyspareunia, vulvar atrophy, vaginal atrophy, vaginal dryness, vulvar itching, vaginal itching, vulvar burning, vaginal burning, vulvar dystrophy, atrophic vaginitis or menopausal sexual dysfunction. In some embodiments, the methods include systemic, for example oral, administration of an estrogen, such as conjugated estrogens, and a progestagen, such as MPA, contemporaneously with local administration of an estrogen, for example conjugated estrogens. In some embodiments, the methods include the oral administration of conjugated estrogens and MPA, and the vulvar, vaginal, or vulvar and vaginal administration of conjugated estrogens, for example in a cream.
Description
field of invention [0001] The present invention relates to methods for the prevention and treatment of conditions caused by localized estrogen deficiency. In some embodiments, the method includes systemically administering an estrogen (eg, conjugated estrogen) and a progestin (eg, medroxyprogesterone acetate (MPA)) concurrently with topical administration of the estrogen. In some embodiments, the method comprises oral administration of the conjugated estrogen and medroxyprogesterone acetate and vulvar, vaginal, or both vulvar and vaginal administration of the conjugated estrogen (eg, in a cream). Background of the invention [0002] Women experience multiple symptoms during menopause, in fact less than 25% of women experience a symptom-free menopausal transition. Menopausal symptoms have a considerable impact on the quality of life (QoL) of women during this period, which are often accompanied by anatomical and physiological changes of the vulva and vagina, decreased vagina...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more